![Kara Stancell](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Kara J.
Stancell is currently the VP-Investor Relations & Corporate Communications at Clarus Therapeutics Holdings, Inc. She previously worked as the Executive Director-Investor Relations at Medicis Pharmaceutical Corp.
from 2010 to 2011 and as the VP-Investor Relations & Corporate Communications at Dermavant Sciences, Inc. from 2018 to 2021.
| Empresas | Cargo | Inicio |
|---|---|---|
| CLARUS THERAPEUTICS HOLDINGS, INC. | Contacto de Relaciones con Inversores | - |
| Empresas | Cargo | Fin |
|---|---|---|
Dermavant Sciences, Inc.
 Dermavant Sciences, Inc. BiotechnologyHealth Technology Operates as a a biotechnology company focused on dermatology | Contacto de Relaciones con Inversores | 01/03/2021 |
| MEDICIS PHARMACEUTICAL CORP | Public Communications Contact | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 3 |
|---|---|
Medicis Pharmaceutical Corp.
 Medicis Pharmaceutical Corp. Pharmaceuticals: MajorHealth Technology Develops and markets pharmaceutical products for dermatological usages | Health Technology |
Dermavant Sciences, Inc.
Dermavant Sciences, Inc. BiotechnologyHealth Technology Operates as a a biotechnology company focused on dermatology | Health Technology |
Clarus Therapeutics Holdings, Inc.
 Clarus Therapeutics Holdings, Inc. BiotechnologyHealth Technology Operates as a pharmaceutical company that develops oral T-replacement therapies | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
